Fat

208 bookmarks
Newest
In Vitro Antiviral Effects of Green-Lipped Mussel Oil and Low-Molecular-Weight Fucoidan on HSV, RSV, and SARS-CoV-2 Pseudovirus
In Vitro Antiviral Effects of Green-Lipped Mussel Oil and Low-Molecular-Weight Fucoidan on HSV, RSV, and SARS-CoV-2 Pseudovirus
Background/Objectives: Marine-derived bioactive compounds have attracted increasing interest due to their potential antiviral properties. This study investigated in vitro antiviral activity of oil extracted from the green-lipped mussel (Perna canaliculus, GLM) and low-molecular-weight (LMW) fucoidan from Undaria pinnatifida against three human viruses in mammalian cell systems. herpes simplex virus-1 (HSV-1), respiratory syncytial virus (RSV), and SARS-CoV-2. These marine compounds were selected with the longer-term aim of evaluating their combination as a potential synergistic antiviral strategy. Methods: Antiviral efficacy was assessed using complementary assay platforms, including plaque reduction assays in mammalian cell systems and a lentiviral pseudovirus system delivering a bioluminescent reporter gene in HEK293/ACE2 cells pseudotyped with the SARS-CoV-2 spike glycoprotein. Cytotoxicity was assessed in parallel, and the selectivity index (SI) was calculated as the ratio of CC50 to IC50 for each compound and virus tested. Results: GLM oil showed potential antiviral activity against SARS-CoV-2 pseudovirus (SI > 6.20), with limited activity against RSV (SI > 3.48) and HSV-1 (SI > 2.28). In contrast, LMW fucoidan did not demonstrate antiviral activity against any of the tested viruses. Conclusions: These findings support further investigation of GLM-derived bioactive compounds as potential antiviral agents, including studies to elucidate their mechanisms of action and in vivo studies to confirm their antiviral efficacy. Combination studies were not pursued in the present work as both compounds require further optimisation individually; however, future studies should evaluate their combined antiviral potential, as synergistic or additive effects remain plausible.
·mdpi.com·
In Vitro Antiviral Effects of Green-Lipped Mussel Oil and Low-Molecular-Weight Fucoidan on HSV, RSV, and SARS-CoV-2 Pseudovirus
John Frederick's Weight Loss Journey
John Frederick's Weight Loss Journey
Roles of diet, exercise, and oral DROP (retatrutide) from The Wellness Company
·thefocalpoints.com·
John Frederick's Weight Loss Journey
OmegaXL
OmegaXL
OmegaXL is a powerful natural supplement shown in clinical research to support joint comfort and function? It contains more than 30 healthy fatty acids, including DHA and EPA. Give it a try, OmegaXL works!
·omegaxl.com·
OmegaXL
The Silent Killer in Your Kitchen! - YouTube
The Silent Killer in Your Kitchen! - YouTube
In this video, Dr. Nathan Bryan debunks the outdated belief that fats cause heart disease, emphasizing that fats are essential for brain function, cell membr...
·youtube.com·
The Silent Killer in Your Kitchen! - YouTube
Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0)
Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0)
There is an urgent need to identify interventions that broadly target aging-related cognitive decline and progression to Alzheimer’s disease (AD). Bottlenose dolphins (Tursiops truncatus) have histologic changes similar to AD in humans, and they also develop shared age-associated co-morbidities identified as risk factors for AD in humans, including type 2 diabetes, ferroptosis, and iron overload, which can be driven by nutritional C15:0 deficiency. We hypothesized that (1) dolphins would have amyloid beta (Aβ) plaques and neuroinflammation that paralleled that of humans in relation to age-related progression, quantitative concentration, and brain region; and (2) C15:0 would have dose-dependent activities relevant to protecting cognitive health. Quantitative immunohistochemistry staining was used to assess 68 tissues from archived brains of 19 Navy dolphins to evaluate associations among amyloid beta (Aβ) plaques and neuroinflammation by brain region, sex, and age group. Further, dose-dependent C15:0 activities, using a third-party panel intended to screen for potential AD therapeutics, were evaluated. Similar to humans, dolphins had the highest Aβ plaque density variation in the hippocampus (90th percentile of 4.95 plaques/mm2), where plaque density increased with age (p = 0.05). All measured markers of neuroinflammation were detected, including the highest concentrations of activated microglia (CD68+) in the hippocampus (0.46 ± 0.38 cells/mm2). C15:0 was a dose-dependent inhibitor of two targets, fatty acid amide hydrolase (FAAH) (IC50 2.5 µM, 89% maximum inhibition at 50 µM relative to URB597) and monoamine oxidase B (MAO-B) (IC50 19.4 µM, 70% maximum inhibition at 50 µM relative to R(-)-Deprenyl). These activities have demonstrated efficacy against Aβ formation and neuroinflammation, including protection of cognitive function in the hippocampus. These findings suggest that, in addition to protecting against AD co-morbidities, C15:0 may play a distinct role in supporting cognitive health, especially at higher concentrations.
·mdpi.com·
Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0)
Seed Oils Fuel Cancer Cell Growth | NaturalHealth365
Seed Oils Fuel Cancer Cell Growth | NaturalHealth365
(NaturalHealth365) New research from UCLA and University of South Florida reveals how seed oils may accelerate cancer growth.
·naturalhealth365.com·
Seed Oils Fuel Cancer Cell Growth | NaturalHealth365
Cellular Fragility Syndrome & C15:0 Deficiency – fatty15
Cellular Fragility Syndrome & C15:0 Deficiency – fatty15
A big paper was just published on a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome. This is a big deal because nutritional deficiency syndromes (like vitamin C deficiency and scurvy, or vitamin D deficiency and rickets) are rarely discovered. This latest paper describes how d
·fatty15.com·
Cellular Fragility Syndrome & C15:0 Deficiency – fatty15
Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health | Scientific Reports
Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health | Scientific Reports
Scientific Reports - Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health
·nature.com·
Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health | Scientific Reports
Fatty15 Patent Positioning: Our Moral & Legal Responsibilities – fatty15
Fatty15 Patent Positioning: Our Moral & Legal Responsibilities – fatty15
Years ago, while helping to continually improve the health and welfare of aging Navy dolphins, our fatty15 founders discovered C15:0 (aka pentadecanoic acid) as the first essential fatty acid to be identified since omega-3, which was over 90 years ago. For more on our founding story, check out our idea-worth-sharing TE
·fatty15.com·
Fatty15 Patent Positioning: Our Moral & Legal Responsibilities – fatty15
US11116740B2 - Methods for use in support of planned supplement and food ingredient products for diagnosis and treatment of metabolic syndrome - Google Patents
US11116740B2 - Methods for use in support of planned supplement and food ingredient products for diagnosis and treatment of metabolic syndrome - Google Patents
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
·patents.google.com·
US11116740B2 - Methods for use in support of planned supplement and food ingredient products for diagnosis and treatment of metabolic syndrome - Google Patents